WEBULL
WebtradeDownload

Neuren Pharmaceuticals (ASX:NEU) Eyes Overseas Growth, Is The Valuation Upside Still There?

Simply Wall St · 1d ago

Neuren Pharmaceuticals (ASX:NEU) has drawn fresh attention after outlining plans to extend its neurology drug portfolio into Canada, Europe, and Japan, with the aim of building new revenue streams and potentially securing higher royalty rates.

At a recent share price of A$20.21, Neuren Pharmaceuticals has seen a 5.32% 1 day share price return and a 19.09% 90 day share price return, while the 1 year total shareholder return is slightly negative and the 5 year total shareholder return is very large. This suggests that longer term holders have still been well rewarded as sentiment improves around its international rollout plans.

Scan other rare-disease and neurology-focused biotechs that may be primed for similar international momentum by starting with our hand-picked 15 high quality undiscovered gems tied to strong underlying fundamentals.

After a sharp swing higher on international hopes, Neuren Pharmaceuticals now asks a simple question of new capital: Does the current price still leave enough upside to justify the clinical and rollout risks ahead?

Most Popular Narrative: 23% Undervalued

Neuren Pharmaceuticals is trading at A$20.21 against a narrative fair value of A$26.11, which frames the stock as attractively priced relative to that estimate while still reminding investors that the story hinges on rare-disease execution and royalty durability.

Biotech companies are always something of a risk. Drug trials can require years of upfront investment, with no guarantee of a positive outcome. Therefore, small pharmaceutical companies that already have an income stream but also have drugs in the later stages of clinical trials can be worth investigating. As such, Neuren Pharmaceuticals (ASX: NEU) is the subject of today’s deep dive.

See why 1 investors see Neuren Pharmaceuticals as 23% undervalued.

According to Robbo, the narrative rests on Neuren Pharmaceuticals combining an existing A$64.6 million royalty stream in 2025 with late stage programs like NNZ-2591. All of this is supported by a cash balance of about A$296 million as of 31 December 2025 that reduces reliance on fresh equity raises. That mix of current income, rare disease focus and a self funded pipeline is what underpins the A$26.11 fair value view and the conclusion that the shares trade at a discount to that narrative today.

Result: Fair Value of A$26.11 (UNDERVALUED)

Still, Neuren Pharmaceuticals faces real pressure points. If DAYBUE royalties disappoint or NNZ-2591 stumbles in Phase 3, either outcome could quickly re-rate the story.

Find out about the key risks to this Neuren Pharmaceuticals narrative.

Another Take On Neuren Pharmaceuticals: Expensive On Earnings

The narrative fair value of A$26.11 paints Neuren Pharmaceuticals as attractively priced, yet the earnings based view tells a different story. At a P/E of 126.5x versus 21.6x for the global pharmaceuticals group, the stock carries a heavy valuation premium that investors cannot ignore.

The gap is just as wide against peers on this metric, where the average sits at 25.6x, and even the estimated fair ratio of 53.9x is less than half Neuren Pharmaceuticals' current level. That kind of stretch can work for you if the pipeline delivers, but what if expectations slip before earnings catch up.

For a closer look at how this earnings multiple compares across sectors and peers, review the valuation breakdown and see what the numbers imply for risk and potential return See what the numbers say about this price — find out in our valuation breakdown.

ASX:NEU P/E Ratio as at Oct 2026
ASX:NEU P/E Ratio as at Oct 2026

Next Steps

Sentiment around Neuren Pharmaceuticals is clearly mixed, with real upside hopes sitting alongside meaningful execution questions, so move quickly and stress test the numbers yourself. To weigh both sides of the argument in one place, start with the 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Neuren Pharmaceuticals?

Do not stop with one opportunity. Broaden your watchlist with focused ideas that match different risk levels and income goals using the Simply Wall St Screener.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.